Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Gross Margin (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Gross Margin readings, the most recent being 85.13% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 436.0% year-over-year to 85.13%, compared with a TTM value of 89.81% through Dec 2025, up 488.0%, and an annual FY2025 reading of 89.81%, up 488.0% over the prior year.
  • Gross Margin hit 85.13% in Q4 2025 for Apellis Pharmaceuticals, down from 94.65% in the prior quarter.
  • The five-year high for Gross Margin was 99.92% in Q4 2021, with the low at 79.4% in Q1 2025.
  • Median Gross Margin over the past 5 years was 88.35% (2024), compared with a mean of 88.93%.
  • The sharpest move saw Gross Margin tumbled -1404bps in 2023, then soared 1170bps in 2025.
  • Year by year, Gross Margin stood at 99.92% in 2021, then decreased by -13bps to 87.09% in 2022, then dropped by -1bps to 86.4% in 2023, then decreased by -7bps to 80.78% in 2024, then grew by 5bps to 85.13% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 85.13%, 94.65%, and 92.37% for Q4 2025, Q3 2025, and Q2 2025 respectively.